Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15652
UPID:
JHD2C_HUMAN
Alternative names:
Jumonji domain-containing protein 1C; Thyroid receptor-interacting protein 8
Alternative UPACC:
Q15652; A0T124; Q5SQZ8; Q5SQZ9; Q5SR00; Q7Z3E7; Q8N3U0; Q96KB9; Q9P2G7
Background:
The Probable JmjC domain-containing histone demethylation protein 2C, also known as Jumonji domain-containing protein 1C and Thyroid receptor-interacting protein 8, plays a pivotal role in the histone code by specifically demethylating 'Lys-9' of histone H3. This action not only alters chromatin structure but also influences gene expression, with implications for hormone-dependent transcriptional activation.
Therapeutic significance:
Understanding the role of Probable JmjC domain-containing histone demethylation protein 2C could open doors to potential therapeutic strategies.